Needham Maintains Buy on Harmonic, Raises Price Target to $17
Needham analyst Ryan Koontz maintains Harmonic (NASDAQ:HLIT) with a Buy and raises the price target from $15 to $17.
Raymond James Maintains Outperform on Harmonic, Raises Price Target to $13
Raymond James analyst Simon Leopold maintains Harmonic (NASDAQ:HLIT) with a Outperform and raises the price target from $12 to $13.
Harmonic: Q2 Earnings Insights
Harmonic (NASDAQ:HLIT) reported its Q2 earnings results on Monday, August 1, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Harmonic beat estimated earnings by 77.78%, reporting an EPS of $0.16 versus an estimate of $0.09.
Earnings Scheduled For August 1, 2022
Companies Reporting Before The Bell
• Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter.
Earnings Preview For Harmonic
Harmonic (NASDAQ:HLIT) is set to give its latest quarterly earnings report on Monday, 2022-08-01. Here's what investors need to know before the announcement.
Analysts estimate that Harmonic will report an earnings per share (EPS) of $0.09.
Rosenblatt Initiates Coverage On Harmonic with Buy Rating, Announces Price Target of $15
Rosenblatt initiates coverage on Harmonic (NASDAQ:HLIT) with a Buy rating and announces Price Target of $15.
80 Biggest Movers From Yesterday
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume.
Barclays Maintains Overweight on Harmonic, Raises Price Target to $13
Barclays analyst Tim Long maintains Harmonic (NASDAQ:HLIT) with a Overweight and raises the price target from $11 to $13.